Market Overview

Antares Pharma Announces Successful Results from VIBEX MTX Trial


Antares Pharma (NASDAQ: ATRS) today announced positive results
from an Actual Human Use (AHU) study for VIBEX Methotrexate (MTX). The
clinical trial was conducted as a multi-center, open-label, single-arm,
in-clinic study to evaluate the actual human use of methotrexate
administered via the VIBEX Medi-Jet in adult patients with rheumatoid
arthritis (RA).

The study assessed the safe usability of VIBEX MTX for
self-administration of parenteral MTX in adult RA patients after
standardized training by site personnel and review of written
instructions. Secondary objectives included evaluation of the
reliability, ease of use and robustness of the VIBEX Medi-Jet; assess
the safety and local tolerance of Medi-Jet administered MTX and to

See full press release

Posted-In: News Guidance Asset Sales Global


Related Articles (ATRS)

View Comments and Join the Discussion!